Bank of New York Mellon Corp raised its position in Spark Therapeutics Inc (NASDAQ:ONCE) by 30.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 152,843 shares of the biotechnology company’s stock after buying an additional 35,722 shares during the period. Bank of New York Mellon Corp owned approximately 0.42% of Spark Therapeutics worth $13,629,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of ONCE. Teacher Retirement System of Texas bought a new position in shares of Spark Therapeutics during the third quarter worth about $225,000. Rhumbline Advisers lifted its position in shares of Spark Therapeutics by 15.6% during the third quarter. Rhumbline Advisers now owns 30,390 shares of the biotechnology company’s stock worth $2,710,000 after purchasing an additional 4,112 shares during the last quarter. Sanctuary Wealth Advisors LLC bought a new position in shares of Spark Therapeutics during the third quarter worth about $3,864,000. Retirement Systems of Alabama bought a new position in shares of Spark Therapeutics during the third quarter worth about $1,881,000. Finally, Alps Advisors Inc. lifted its position in shares of Spark Therapeutics by 25.6% during the third quarter. Alps Advisors Inc. now owns 35,281 shares of the biotechnology company’s stock worth $3,146,000 after purchasing an additional 7,184 shares during the last quarter. 94.91% of the stock is owned by institutional investors.
ONCE has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Wednesday, October 25th. UBS Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $92.00 to $51.00 in a research report on Tuesday, December 12th. Raymond James Financial initiated coverage on shares of Spark Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $96.00 price target on the stock. Cantor Fitzgerald set a $105.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 11th. Finally, Leerink Swann cut shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 price target on the stock. in a research report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $76.03.
In other Spark Therapeutics news, insider Daniel Faga sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total value of $607,200.00. Following the sale, the insider now owns 6,000 shares in the company, valued at $485,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at approximately $581,950.24. The disclosure for this sale can be found here. Insiders sold 62,309 shares of company stock worth $4,621,085 in the last 90 days. 7.30% of the stock is owned by company insiders.
Shares of Spark Therapeutics Inc (NASDAQ ONCE) traded down $1.41 during trading hours on Friday, hitting $52.66. 712,141 shares of the company’s stock traded hands, compared to its average volume of 1,560,000. Spark Therapeutics Inc has a 12 month low of $41.06 and a 12 month high of $91.75. The firm has a market capitalization of $1,950.00 and a price-to-earnings ratio of -7.31.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same quarter in the previous year, the business posted ($1.07) EPS. Spark Therapeutics’s revenue for the quarter was up 45.8% compared to the same quarter last year. analysts anticipate that Spark Therapeutics Inc will post -7.55 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics Inc (NASDAQ:ONCE) Shares Bought by Bank of New York Mellon Corp” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/spark-therapeutics-inc-once-holdings-raised-by-bank-of-new-york-mellon-corp.html.
Spark Therapeutics Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.